Jacob Fiksel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacob Fiksel has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Robert B. Scharpf
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
83 shared publications - Valsamo Anagnostou
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
57 shared publications - Alexander S. Baras
Department of Pathology, The Johns Hopkins University, Baltimore, USA
56 shared publications - Andrew S. Park
Center for Observational Research, Amgen Inc., Thousand Oaks, California
56 shared publications - Archana Balan
The Sidney Kimmel Comprehensive Cancer Center 1 , Johns Hopkins University School of Medicine, Baltimore, Maryland
56 shared publications - Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
56 shared publications
Latest Publications
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Kaplan-Meier survival curves for ovarian cancer patients with and without mutations in the PI3K and WNT pathways. (a, b) Alterations in the PI3K pathway trended towards increased survival among patients with ovarian endometrioid carcinomas and decreased survival among patients with ovarian mucinous carcinomas. (c) CTNNB1 alternations in the WNT pathway trended towards association with increased survival among patients with ovarian endometrioid carcinomas.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Kaplan-Meier survival curves for ovarian cancer patients with and without mutations in the PI3K and WNT pathways. (a, b) Alterations in the PI3K pathway trended towards increased survival among patients with ovarian endometrioid carcinomas and decreased survival among patients with ovarian mucinous carcinomas. (c) CTNNB1 alternations in the WNT pathway trended towards association with increased survival among patients with ovarian endometrioid carcinomas.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Summary of next-generation sequencing analyses.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Summary of next-generation sequencing analyses.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Amplifications from whole genome analyses.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Amplifications from whole genome analyses.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Deletions from whole genome analyses.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Deletions from whole genome analyses.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Circos plots of colorectal mucinous carcinoma samples.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Circos plots of colorectal mucinous carcinoma samples.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Rearrangements of ovarian endometrioid and ovarian mucinous carcinomas identified by TRELLIS. Rearrangements present in ovarian endometrioid carcinomas CGOV161T and CGOV172T (a, b) and an ovarian mucinous tumor CGOV173T (c). Split reads that span the fusion junction are shown in black, while read pairs that reside on either side of the junction are shown in green and blue.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Rearrangements of ovarian endometrioid and ovarian mucinous carcinomas identified by TRELLIS. Rearrangements present in ovarian endometrioid carcinomas CGOV161T and CGOV172T (a, b) and an ovarian mucinous tumor CGOV173T (c). Split reads that span the fusion junction are shown in black, while read pairs that reside on either side of the junction are shown in green and blue.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Summary of ovarian, uterine, and GI tumors analyzed through whole exome and whole genome analyses.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Summary of ovarian, uterine, and GI tumors analyzed through whole exome and whole genome analyses.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Somatic sequence alterations from whole exome analyses.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Somatic sequence alterations from whole exome analyses.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Mutations in ESR1 at Tyr537 and Leu536. ESR1 mutations identified in two patients with uterine endometrioid carcinomas occurred at Tyr537, a hotspot most commonly associated with aromatase inhibitor resistance in patients with breast cancer patients, and Leu536. This hotspot is in close proximity to the region of the estrogen receptor that is important for ligand-dependent transcriptional function. The Tyr537 mutations cause a conformational change that constitutively activates the receptor independent of estrogen receptor binding. The Tyr537 residue is highlighted in blue in a three-dimensional view of the ESR1 protein (bottom). Due to its physical proximity to the Tyr537 hotspot, the Leu536 mutation is likely to have the same activating effect on the estrogen receptor.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Mutations in ESR1 at Tyr537 and Leu536. ESR1 mutations identified in two patients with uterine endometrioid carcinomas occurred at Tyr537, a hotspot most commonly associated with aromatase inhibitor resistance in patients with breast cancer patients, and Leu536. This hotspot is in close proximity to the region of the estrogen receptor that is important for ligand-dependent transcriptional function. The Tyr537 mutations cause a conformational change that constitutively activates the receptor independent of estrogen receptor binding. The Tyr537 residue is highlighted in blue in a three-dimensional view of the ESR1 protein (bottom). Due to its physical proximity to the Tyr537 hotspot, the Leu536 mutation is likely to have the same activating effect on the estrogen receptor.
- Open Access
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Circos plots of uterine endometrioid carcinoma samples.
- 5 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types
Circos plots of uterine endometrioid carcinoma samples.